Home
Company
Corporate Overview
Management Team
Key Personnel
Advisors
Products
Overview
Substance P and Homspera
Development Activities
Applications
Public Relations
Press Releases
Media Coverage
News Archive
Investors
Investor Info
SEC Filings
SEC Filings (ownership only)
Code of Ethics
Shareholder Letters
Contact
News
ImmuneRegen News
ImmuneRegen Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board
December 1, 2008
ImmuneRegen BioSciences to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
November 6, 2008
ImmuneRegen Scientist to Present Viprovex® Pre-Clinical Study Findings at 2008 BARDA Industry Day
September 24, 2008
UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegen's Viprovex® With Cancer Vaccine
September 23, 2008
ASU's Biodesign Institute and ImmuneRegen Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses
August 18, 2008
ImmuneRegen® BioSciences Confirms Homspera® Advances Wound Healing in Topical Application
August 13, 2008
IR BioSciences Holdings, Inc. Closes New $5 Million Funding Round
August 11, 2008
ImmuneRegen(R) BioSciences Advances Toward IND Filing
July 17, 2008
ImmuneRegen® BioSciences Confirms Adult Stem Cell Activity of Homspera® in Human Bone Marrow
June 9, 2008
ImmuneRegen® Appoints Renowned Hematologist Ivan N. Rich, Ph.D. to Advisory Board
May 6, 2008
ImmuneRegen(R) BioSciences to Provide Adjuvant to DynPort Vaccine Company for Development of an Inactivated Vaccine against Venezuelan Equine Encephalitis Virus
April 30, 2008
ImmuneRegen(R) and BioCure Collaborate on Novel Wound-Healing Product
April 24, 2008
ImmuneRegen Releases Results from UMDNJ Study Confirming Homspera's Adult Stem Cell Activity
April 16, 2008
ImmuneRegen® BioSciences Signs Material Transfer Agreement with University of Medicine and Dentistry of New Jersey
April 1, 2008
ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity
March 27, 2008
ImmuneRegen® BioSciences and DelSite Biotechnologies Collaborate On New Flu Treatment
March 24, 2008
ImmuneRegen BioSciences Signs Lovelace Respiratory Research Institute as Development and Regulatory Partner
February 19, 2008
ImmuneRegen BioSciences Announces Material Transfer Agreement with HemoGenix®
January 28, 2008
ImmuneRegen BioSciences Signs Material Transfer Agreement with Celgene Cellular Therapeutics
January 23, 2008
IR BioSciences Announces $3 Million Financing Agreement
January 9, 2008
Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved.